keyword
https://read.qxmd.com/read/38696845/identification-of-fty720-and-coh29-as-novel-topoisomerase-i-catalytic-inhibitors-by-experimental-and-computational-studies
#1
JOURNAL ARTICLE
Huang Zeng, Shengyuan Zhang, Hua Nie, Junhao Li, Jiunlong Yang, Yuanbei Zhuang, Yingjie Huang, Miao Zeng
The development of novel topoisomerase I (TOP1) inhibitors is crucial for overcoming the drawbacks and limitations of current TOP1 poisons. Here, we identified two potential TOP1 inhibitors, namely, FTY720 (a sphingosine 1-phosphate antagonist) and COH29 (a ribonucleotide reductase inhibitor), through experimental screening of known active compounds. Biological experiments verified that FTY720 and COH29 were nonintercalative TOP1 catalytic inhibitors that did not induce the formation of DNA-TOP1 covalent complexes...
April 29, 2024: Bioorganic Chemistry
https://read.qxmd.com/read/38696844/molecular-docking-approach-for-the-design-and-synthesis-of-new-pyrazolopyrimidine-analogs-of-roscovitine-as-potential-cdk2-inhibitors-endowed-with-pronounced-anticancer-activity
#2
JOURNAL ARTICLE
Ola Alaa Hamed, Nehad Abou-Elmagd El-Sayed, Walaa R Mahmoud, Ghada F Elmasry
Cyclin-dependent kinase 2 (CDK2) is a vital protein for controlling cell cycle progression that is critically associated with various malignancies and its inhibition could offer a convenient therapeutic approach in designing anticancer remedies. Consequently, this study aimed to design and synthesize new CDK2 inhibitors featuring roscovitine as a template model. The purine ring of roscovitine was bioisosterically replaced with the pyrazolo[3,4-d]pyrimidine scaffold, in addition to some modifications in the side chains...
April 30, 2024: Bioorganic Chemistry
https://read.qxmd.com/read/38696831/medication-use-before-and-after-bariatric-surgery-5-year-results-from-a-randomised-controlled-trial-of-banded-roux-en-y-gastric-bypass-versus-sleeve-gastrectomy-in-patients-with-obesity-and-type-2-diabetes
#3
RANDOMIZED CONTROLLED TRIAL
James Tan, Talat Nur, Bronwen Jones, Rinki Murphy, David Kim, Richard Cutfield, Lindsay D Plank, Michael Booth
AIM: Bariatric surgery is an effective tool for weight loss and for improving weight related co-morbidities. Changes in medication usage after a silastic ring laparoscopic Roux-en-Y gastric bypass (SR-LRYGB) compared with laparoscopic sleeve gastrectomy (LSG) are unknown. METHODS: This was a single-centre, double-blind, randomised controlled trial. Patients were randomised to either SR-LRYGB or LSG. A medication history was obtained at regular follow-up intervals, and mean numbers of prescribed medications were analysed over 5 years...
May 3, 2024: New Zealand Medical Journal
https://read.qxmd.com/read/38696829/dispensing-of-attention-deficit-hyperactivity-disorder-medications-for-adults-in-aotearoa-new-zealand
#4
JOURNAL ARTICLE
Ben Beaglehole, Stephen Jarman, Chris Frampton
AIM: To report dispensing trends for attention-deficit hyperactivity disorder (ADHD) in Aotearoa New Zealand, focussing on adults in order to highlight increasing demand for ADHD treatment by adults and to prompt discussion. METHOD: Demographic and dispensing data for ADHD were obtained from the Pharmaceutical Collection between the years 2006 and 2022. This was stratified according to child (<18 years) and adult (≥18 years) populations. Population dispensing rates for methylphenidate and atomoxetine were calculated...
May 3, 2024: New Zealand Medical Journal
https://read.qxmd.com/read/38696747/real-world-patterns-and-sequences-of-targeted-therapy-use-in-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma-in-the-united-states-a-longitudinal-study
#5
JOURNAL ARTICLE
Scott F Huntington, Wendy Y Cheng, Eric M Sarpong, Siyang Leng, Mohammed Z H Farooqui, Uchechukwu Samuel Agu, Maryaline Catillon, Dominique Lejeune, Nathaniel Downes, Lisa Matay, Mei Sheng Duh, Enrico De Nigris
With increasing focus on novel targeted therapies for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), this longitudinal claims-based study evaluated real-world CLL/SLL treatment sequences, particularly sequential targeted therapy. Among patients with first-line (1 L) treatment in 2014-2017 ( N  = 2,612; median follow-up = 3 years), the most common 1 L treatment was chemoimmunotherapy (CIT; 44.6%), followed by CD20 (25.2%) and Bruton's tyrosine kinase inhibitors (BTKi; 21...
May 2, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38696737/mog-antibody-associated-disease-in-the-setting-of-metastatic-melanoma-complicated-by-immune-checkpoint-inhibitor-use
#6
JOURNAL ARTICLE
Stephanie B Syc-Mazurek, Hannah Zhao-Fleming, Yong Guo, Nanthaya Tisavipat, John J Chen, Anastasia Zekeridou, Ioannis Kournoutas, Jacob J Orme, Matthew S Block, Claudia F Lucchinetti, Rafid Mustafa, Eoin P Flanagan
OBJECTIVES: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an autoimmune demyelinating disease rarely associated with malignancy. We report the clinical, MRI, immunopathology, and treatment response in a person with MOGAD and melanoma. METHODS: This is a case report of a person with a multidisciplinary evaluation at a tertiary referral center. RESULTS: A 52-year-old man presented with progressive encephalomyelitis that led to identification of metastatic melanoma...
July 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38696722/modular-and-integrative-activity-reporters-enhance-biochemical-studies-in-the-yeast-er
#7
JOURNAL ARTICLE
Samantha G Martinusen, Ethan W Slaton, Sage E Nelson, Marian A Pulgar, Julia T Besu, Cassidy F Simas, Carl A Denard
The yeast endoplasmic reticulum sequestration and screening (YESS) system is a generalizable platform that has become highly useful to investigate post-translational modification enzymes (PTM-enzymes). This system enables researchers to profile and engineer the activity and substrate specificity of PTM-enzymes and to discover inhibitor-resistant enzyme mutants. In this study, we expand the capabilities of YESS by transferring its functional components to integrative plasmids. The YESS integrative system yields uniform protein expression and protease activities in various configurations, allows one to integrate activity reporters at two independent loci and to split the system between integrative and centromeric plasmids...
May 2, 2024: Protein Engineering, Design & Selection: PEDS
https://read.qxmd.com/read/38696711/cardiovascular-toxicity-of-bruton-tyrosine-kinase-inhibitors-forget-about-selectivity-but-watch-the-clock
#8
JOURNAL ARTICLE
Giorgio Minotti
No abstract text is available yet for this article.
May 2, 2024: Blood Advances
https://read.qxmd.com/read/38696710/patient-with-mediastinal-carcinoma-of-unknown-primary-with-ret-fusion-achieves-durable-response-with-ret-inhibition
#9
JOURNAL ARTICLE
Adam Barsouk, Omar Elghawy, Sara Stone, Aditi Singh
Selective RET inhibitors have shown promise in thyroid cancer (TC) and nonsmall cell lung cancer (NSCLC) harboring RET fusions on next-generation sequencing (NGS), although rarity of the rearrangement has led to limited data for certain tumor types, such as carcinoma of unknown primary. We present a 65-year-old female with no history of malignancy, smoking or radiation exposure, who was found to have an anterior mediastinum malignancy of unknown primary, with metastases to supraclavicular lymph nodes. Core biopsy of the mediastinum revealed poorly differentiated carcinoma, while a biopsy of the thyroid revealed atypia of indeterminate significance (Bethesda III)...
April 29, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38696696/healthcare-resource-utilization-and-costs-among-patients-with-alpha-1-antitrypsin-deficiency-with-liver-and-or-lung-disease-a-longitudinal-retrospective-study-in-the-usa
#10
JOURNAL ARTICLE
May Hagiwara, Victoria Divino, Swapna Munnangi, Mark Delegge, Suna Park, Ed G Marins, Kaili Ren, Charlie Strange
Aim: To evaluate all-cause and liver-associated healthcare resource utilization (HCRU) and costs among patients with alpha-1 antitrypsin deficiency (AATD) with liver disease (LD) and/or lung disease (LgD). Materials & methods: This was a retrospective analysis of linked administrative claims data from the IQVIA PharMetrics® Plus and the IQVIA Ambulatory Electronic Medical Records (AEMR) databases from 1 July 2021 to 31 January 2022. Patients with AATD in the IQVIA PharMetrics Plus database were included with ≥1 inpatient or ≥2 outpatient medical claims ≥90 days apart with a diagnosis of AATD, or with records indicating a protease inhibitor (Pi)*ZZ/Pi*MZ genotype in the IQVIA AEMR database with linkage to IQVIA PharMetrics Plus...
May 2, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38696610/inhibition-of-mettl3-alleviates-nlrp3-inflammasome-activation-via-increasing-ubiquitination-of-nek7
#11
JOURNAL ARTICLE
Xinyi Zhou, Xiaoyu Yang, Shenzhen Huang, Guifeng Lin, Kexin Lei, Qian Wang, Weimin Lin, Hanwen Li, Xingying Qi, Dutmanee Seriwatanachai, Shengyong Yang, Bin Shao, Quan Yuan
N6-methyladenosine (m6 A) modification, installed by METTL3-METTL14 complex, is abundant and critical in eukaryotic mRNA. However, its role in oral mucosal immunity remains ambiguous. Periodontitis is a special but prevalent infectious disease characterized as hyperinflammation of oral mucosa and bone resorption. Here, it is reported that genetic deletion of Mettl3 alleviates periodontal destruction via suppressing NLRP3 inflammasome activation. Mechanistically, the stability of TNFAIP3 (also known as A20) transcript is significantly attenuated upon m6 A modification...
May 2, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
https://read.qxmd.com/read/38696509/efficacy-and-safety-of-tegoprazan-in-the-treatment-of-gastroesophageal-reflux-disease-a-protocol-for-meta-analysis-and-systematic-review
#12
JOURNAL ARTICLE
Hanxue Zheng, Shunqi Yuan, Jianmin Liu
OBJECTIVE: The incidence of gastroesophageal reflux disease (GERD) is increasing year by year, the clinical manifestations are complex and diverse, and the adverse effects of long-term use of proton pump inhibitors and gastrointestinal motility drugs have been of great concern in recent years. The effectiveness of tegoprazan in the treatment of GERD is still controversial. This protocol describes a systematic review and meta-analysis to evaluate the efficacy and safety of tegoprazan in the treatment of gastroesophageal reflux disease...
2024: PloS One
https://read.qxmd.com/read/38696474/immunomodulation-of-salivary-gland-function-due-to-cancer-therapy
#13
REVIEW
Ana C Costa-da-Silva, Carlos U Villapudua, Matthew P Hoffman, Marit H Aure
Functional salivary glands (SG) are essential for maintaining oral health, and salivary dysfunction is a persistent major clinical challenge. Several cancer therapies also have off-target effects leading to SG dysfunction. Recent advances highlight the role of SG immune populations in homeostasis, dysfunction and gland regeneration. Here, we review what is known about SG immune populations during development and postnatal homeostasis. We summarize recent findings of immune cell involvement in SG dysfunction following cancer treatments such as irradiation (IR) for head and neck cancers, immune transplant leading to graft-versus-host-disease (GVHD) and immune checkpoint inhibitor (ICI) treatment...
May 2, 2024: Oral Diseases
https://read.qxmd.com/read/38696316/erdafitinib-balversa-for-urothelial-carcinoma
#14
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
May 13, 2024: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/38696259/verteporfin-inhibits-tgf-%C3%AE-signaling-by-disrupting-the-smad2-3-smad4-interaction
#15
JOURNAL ARTICLE
Junxiu Nong, Shengqiang Shen, Fan Hong, Fan Xiao, Lingtian Meng, Pilong Li, Xiaoguang Lei, Ye-Guang Chen
Transforming growth factor-β (TGF-β) signaling plays a crucial role in pathogenesis, such as accelerating tissue fibrosis and promoting tumor development at the later stages of tumorigenesis by promoting epithelial-mesenchymal transition, cancer cell migration, and invasion. Targeting TGF-β signaling is a promising therapeutic approach, but non-specific inhibition may result in adverse effects. In this study, we focus on the Smad2/3-Smad4 complex, a key component in TGF-β signaling transduction, as a potential target for cancer therapy...
May 2, 2024: Molecular Biology of the Cell
https://read.qxmd.com/read/38696257/btk-drives-neutrophil-activation-for-sterilizing-antifungal-immunity
#16
JOURNAL ARTICLE
Jigar V Desai, Marissa A Zarakas, Andrew L Wishart, Mark Roschewski, Mariano A Aufiero, Ágnes Donkó, Gustaf Wigerblad, Neta Shlezinger, Markus Plate, Matthew R James, Jean K Lim, Gulbu Uzel, Jenna Re Bergerson, Ivan Fuss, Robert A Cramer, Luis M Franco, Emily S Clark, Wasif N Khan, Daisuke Yamanaka, Georgios Chamilos, Jamel El-Benna, Mariana J Kaplan, Louis M Staudt, Thomas L Leto, Steven M Holland, Wyndham H Wilson, Tobias M Hohl, Michail S Lionakis
We describe a previously-unappreciated role for Bruton's tyrosine kinase (BTK) in fungal immune surveillance against aspergillosis, an unforeseen complication of BTK inhibitors (BTKi) used for treating B-cell lymphoid malignancies. We studied BTK-dependent fungal responses in neutrophils from diverse populations, including healthy donors, BTKi-treated patients, and X-linked agammaglobulinemia patients. Upon fungal exposure, BTK was activated in human neutrophils in a TLR2-, Dectin-1-, and FcγR-dependent manner, triggering the oxidative burst...
May 2, 2024: Journal of Clinical Investigation
https://read.qxmd.com/read/38696235/online-patient-attitudes-toward-cutaneous-immune-related-adverse-events-attributed-to-nivolumab-and-pembrolizumab-sentiment-analysis
#17
JOURNAL ARTICLE
Camille M Powers, Andrew K Yang, Hannah Verma, Jeremy Orloff, Austin J Piontkowski, Nicholas Gulati
No abstract text is available yet for this article.
May 2, 2024: JMIR dermatology
https://read.qxmd.com/read/38696223/from-bench-to-bedside-is-there-a-role-of-il-17-drugs-in-rheumatoid-arthritis
#18
REVIEW
Swetha Byravan, Harini Samarasinghe, Jack Shi Jie Yuan, Syed Haider Tahir, Arumugam Moorthy, Hasan Tahir
INTRODUCTION: IL-17 has been described as a pro-inflammatory cytokine that is relevant in the seronegative spondylarthritides with IL-17 targeted therapies being licensed for their treatment.There is evidence to demonstrate that IL-17 is found in RA joints and contributes to the pro-inflammatory cascade. This results in synovial hyperplasia and osteoclastogenesis thus causing joint destruction and bony erosions. AREAS COVERED: This review article summarizes trials that have studied the use of IL-17 targeted therapies in RA patients who have failed conventional synthetic disease-modifying therapy (C-DMARDS) and biologic DMARDS...
May 2, 2024: Expert Opinion on Investigational Drugs
https://read.qxmd.com/read/38696170/comparative-outcomes-of-empagliflozin-to-dapagliflozin-in-patients-with-heart-failure
#19
MULTICENTER STUDY
Katherine L Modzelewski, Alexandra Pipilas, Nicholas A Bosch
IMPORTANCE: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been shown to have benefits when used in patients with heart failure. The comparative outcomes of SGLT2 inhibitors relative to each other has not been well defined and may impact medication selection. OBJECTIVE: To determine the comparative outcomes of empagliflozin and dapagliflozin on reducing the composite of all-cause mortality and hospitalizations in patients with heart failure. DESIGN, SETTING, AND PARTICIPANTS: This multicenter retrospective cohort study included patients with heart failure from August 18, 2021, and December 6, 2022, in the TriNetX Research Collaborative, a centralized database of deidentified electronic medical record data from a network of 81 health care organizations...
May 1, 2024: JAMA Network Open
https://read.qxmd.com/read/38696168/treatment-patterns-and-attrition-with-lines-of-therapy-for-advanced-urothelial-carcinoma-in-the-us
#20
JOURNAL ARTICLE
Vinay Mathew Thomas, Yeonjung Jo, Nishita Tripathi, Soumyajit Roy, Beverly Chigarira, Arshit Narang, Georges Gebrael, Chadi Hage Chehade, Nicolas Sayegh, Gliceida Galarza Fortuna, Richard Ji, Patrick Campbell, Haoran Li, Neeraj Agarwal, Sumati Gupta, Umang Swami
IMPORTANCE: The treatment paradigm for advanced urothelial carcinoma (aUC) has undergone substantial transformation due to the introduction of effective, novel therapeutic agents. However, outcomes remain poor, and little is known about current treatment approaches and attrition rates for patients with aUC. OBJECTIVES: To delineate evolving treatment patterns and attrition rates in patients with aUC using a US-based patient-level sample. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used patient-level data from the nationwide deidentified electronic health record database Flatiron Health, originating from approximately 280 oncology clinics across the US...
May 1, 2024: JAMA Network Open
keyword
keyword
846
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.